10-K/A: HOOKIPA Pharma Files Amendment to 10-K to Include Omitted Information on Directors, Executive Pay, and Governance

Sentiment:

Form 10-K/A Amendment 30 April 2025 5:03 PM

HOOKIPA Pharma Inc. filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive compensation, and corporate governance.

Capital raiseThe company may require Gilead to purchase the balance of $8.7 million of common stock as participation in potential future equity raises.Our right to sell shares of our common stock to Gilead is subject to specified limitations, including a limitation that prevents us from requesting purchases of shares of common stock by Gilead that would result in a beneficial ownership of more than 19.9% of the total number of outstanding shares of common stock by Gilead.

Summary

HOOKIPA Pharma Inc. filed Amendment No. 1 to its Form 10-K/A to include information required by Items 10 through 14 of Part III of Form 10-K, which were initially omitted.
The amendment also updates the exhibit list in Item 15 of Part IV of the original 10-K.
The information pertains to directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and principal accountant fees.
The amendment includes new certifications by the company's principal executive officer and principal financial officer.
The aggregate market value of the Registrant's Common Stock held by non-affiliates on June 30, 2024 was approximately $57.0 million.
As of April 25, 2025, there were 9,782,872 shares of common stock and 2,399,517 shares of Class A common stock outstanding.

Sentiment

Score: 7

Explanation: The document is primarily factual and related to regulatory compliance. The sentiment is neutral to slightly positive due to the inclusion of information about corporate governance and executive compensation, which can be seen as a sign of transparency.

Positives

The company has adopted a Code of Business Conduct and Ethics to ensure integrity and ethical business practices.
The Board of Directors has an Audit Committee composed of independent members with financial expertise.
The company maintains an Insider Trading Policy to promote compliance with insider trading laws.
The company has a Clawback Policy to recover erroneously awarded incentive-based compensation from executive officers in the event of an accounting restatement.

Negatives

Gamida Cell Ltd., where Terry Coelho previously served as CFO, filed a voluntary proceeding for restructuring in March 2024.
Two directors, Jan van de Winkel and Timothy Reilly, resigned from the Board of Directors effective August 30, 2024.
Joern Aldag and Reinhard Kandera separated from their positions as CEO and CFO, respectively, effective July 22, 2024.

Risks

The company's success depends on attracting and retaining qualified executives and directors.
Potential conflicts of interest may arise in related party transactions.
The company's financial results could be negatively impacted by material noncompliance with financial reporting requirements.

Future Outlook

The document does not contain specific forward-looking statements beyond the standard business operations and agreements.

Industry Context

HOOKIPA Pharma is operating in the competitive biotechnology industry, focusing on developing immunotherapies. The collaboration with Gilead Sciences highlights the industry trend of partnerships between larger pharmaceutical companies and smaller biotech firms to advance drug development.

Comparison to Industry Standards

Executive compensation packages at HOOKIPA Pharma are generally in line with industry standards for similarly sized biotechnology companies.
The company's corporate governance practices, including the establishment of an audit committee and a code of ethics, align with best practices in the biotechnology industry.
The collaboration agreement with Gilead Sciences is a common strategy in the biotech industry, similar to partnerships between companies like BioNTech and Pfizer, or Moderna and Merck, to leverage resources and expertise.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Executive Officer and President	Joern Aldag	Malte Peters	July 22, 2024	Separation of Joern Aldag
Executive Vice President and Chief Financial Officer	Reinhard Kandera	Terry Coelho	July 22, 2024	Separation of Reinhard Kandera

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Code of Business Conduct and Ethics	The Board of Directors has adopted a Code of Business Conduct and Ethics, which applies to our directors, officers and employees.	N/A	Ensures ethical business practices and compliance with laws.
Clawback Policy	The Board of Directors adopted the HOOKIPA Pharma Inc. Clawback Policy, which is intended to comply with the final clawback rules adopted by the SEC.	N/A	Allows the company to recover erroneously awarded incentive-based compensation from executive officers in the event of an accounting restatement.
Non-Employee Director Compensation Policy	In March 2024, the policy was amended to provide that each non-employee director will receive an initial, one-time stock option grant to purchase 9,800 shares of our common stock and each continuing non-employee member of the board will receive, at the time of the Companys annual meeting, an annual grant of options to purchase 4,900 shares of our common stock (or, for the Non-Executive Chair of our Board, 9,800 shares of our common stock).	March 2024	Designed to attract and retain high caliber non-employee directors.

Related Party Transactions

The company has a collaboration and license agreement with Gilead Sciences, Inc., a holder of greater than five percent of our capital stock.
The company entered into a stock purchase agreement with Gilead, a holder of greater than five percent of our capital stock, that requires Gilead, at our option, to purchase up to $35.0 million of our common stock.

Stakeholder Impact

Shareholders are provided with detailed information about executive compensation and corporate governance.
Employees are subject to the Code of Business Conduct and Ethics and the Insider Trading Policy.
The company's financial performance and strategic decisions impact its stakeholders, including shareholders, employees, and partners.

Next Steps

The company will continue to execute its business strategy and development programs.
The company will hold its annual meeting of stockholders.
The company will continue to comply with SEC reporting requirements.

Key Dates

Date	Description
June 2018	HOOKIPA entered into a collaboration and license agreement with Gilead Sciences, Inc.
January 2023	Malte Peters joined the Board of Directors.
April 7, 2023	Board of Directors adopted the 2023 Inducement Plan.
April 2023	Terry Coelho joined the Board of Directors.
May 2023	Terry Coelho served as Chief Financial Officer of Gamida Cell Ltd.
July 2024	Malte Peters appointed as Chief Executive Officer and President, Terry Coelho appointed as Executive Vice President and Chief Financial Officer, Joern Aldag and Reinhard Kandera separated from their positions.
August 30, 2024	Jan van de Winkel and Timothy Reilly resigned as members of the Board of Directors.
March 31, 2025	Information about directors and executive officers as of this date.
April 25, 2025	Number of outstanding shares of Common Stock as of this date.
April 30, 2025	Date of filing this Amendment No. 1 to Form 10-K/A.

Keywords

executive compensation, corporate governance, directors, audit fees, security ownership, related transactions, stock options, HOOKIPA Pharma, 10-K/A

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.